Home > News > BioSante Pharmaceuticals Signs License Option Agreement
September 14th, 2005
BioSante Pharmaceuticals Signs License Option Agreement
Abstract:
BioSante Pharmaceuticals, Inc. today announced that it has signed a Material Transfer and Option Agreement with an undisclosed European pharmaceutical company for an exclusive option to obtain an exclusive, worldwide license to use BioSante's calcium phosphate nanotechnology (CaP) in the development of a series of allergy products.
Source:
businesswire
Bookmark:
Investments/IPO's/Splits
Elsevier Business Intelligence (EBI) to Host 'IN3 Medical Device 360 Boston,' June 24-26, 2013 May 20th, 2013
Aspen Aerogels Announces $22.5 Million Private Placement May 18th, 2013
Harris & Harris Group Notes the Sale of a Second D-Wave Quantum Computer May 16th, 2013
Nanometrics Announces Upcoming Investor Events May 14th, 2013
Nanomedicine
Nano-needles for cells May 25th, 2013
UofL scientists uncover how grapefruits provide a secret weapon in medical drug delivery May 22nd, 2013
Single-Cell Transfection Tool Enables Added Control for Biological Studies: McCormick researchers develop method of delivering molecules into targeted cells May 22nd, 2013
How Gold Nanoparticles Can Help Fight Ovarian Cancer May 21st, 2013
Announcements
Nano-needles for cells May 25th, 2013
How do cold ions slide May 24th, 2013
Gold nanocrystal vibration captured on billion-frames-per-second film May 23rd, 2013
Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home: Glowing Plant seeks funds via crowdfunding and raises almost $400,000 May 23rd, 2013